Guiling Xiang1, Liang Xie1, Zhihong Chen1, Shengyu Hao1, Cuiping Fu1, Qinhan Wu1, Xuhui Liu2, Shanqun Li3. 1. Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital Fudan University, Shanghai, China. 2. Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital Fudan University, Shanghai, China. liuxuhui@shphc.org.cn. 3. Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital Fudan University, Shanghai, China. li.shanqun@zs-hospital.sh.cn.
Abstract
BACKGROUND: New evidence from retrospective cohort studies on risk of death from COVID-19 infection became available. We aimed to systematically review the clinical risk factors for fatal outcome of COVID-19. METHODS: We performed meta-analysis, using PubMed, EMBASE and Cochrane databases from December 1 2019 to June 10 2020. The meta-analysis summarized clinical, laboratory, radiological features, and complications of non-survivors with confirmed COVID-19. In addition, a fixed- or random-effects model was adopted based on the heterogeneity among studies. We also used funnel-plot with Egger's tests to screen potential publication bias. RESULTS: In total, twenty studies with 15,408 COVID-19 cases were included in our meta-analysis. Male, current smoking, and older age were associated with in-hospital death. Patients aged 60 years or over had the highest pooled ORs [OR 4.94 (2.89, 8.44)]. Non-survivors were more likely to have diabetes, hypertension, cardiovascular disease (CVD), respiratory disease, or chronic kidney disease (CKD). Respiratory disease had the highest pooled ORs [OR 2.55 (2.14, 3.05)]. Dyspnea [OR 3.31 (1.78, 6.16); I2 : 83%] and fatigue [OR 1.36 (1.07, 1.73); I2 : 0%] were associated with increased risk of death. Increased white blood cell count, decreased lymphocyte and platelet counts, were also associated with increased risk of death. Biomarkers of coagulation function, inflammation, liver and kidney function, cardiac and muscle injury were also elevated in nonsurvivors. CONCLUSIONS: Male, current smoking patients aged 60 years or over might face a greater risk of in-hospital death and the comorbidities such as diabetes, hypertension, CVD, respiratory disease, and CKD could also influence the prognosis of the COVID-19. Clinical feature such as dyspnea and fatigue could imply the exacerbation and even death. Our findings highlighted early markers of mortality which were beneficial to identify fatal COVID-19.
BACKGROUND: New evidence from retrospective cohort studies on risk of death from COVID-19infection became available. We aimed to systematically review the clinical risk factors for fatal outcome of COVID-19. METHODS: We performed meta-analysis, using PubMed, EMBASE and Cochrane databases from December 1 2019 to June 10 2020. The meta-analysis summarized clinical, laboratory, radiological features, and complications of non-survivors with confirmed COVID-19. In addition, a fixed- or random-effects model was adopted based on the heterogeneity among studies. We also used funnel-plot with Egger's tests to screen potential publication bias. RESULTS: In total, twenty studies with 15,408 COVID-19 cases were included in our meta-analysis. Male, current smoking, and older age were associated with in-hospital death. Patients aged 60 years or over had the highest pooled ORs [OR 4.94 (2.89, 8.44)]. Non-survivors were more likely to have diabetes, hypertension, cardiovascular disease (CVD), respiratory disease, or chronic kidney disease (CKD). Respiratory disease had the highest pooled ORs [OR 2.55 (2.14, 3.05)]. Dyspnea [OR 3.31 (1.78, 6.16); I2 : 83%] and fatigue [OR 1.36 (1.07, 1.73); I2 : 0%] were associated with increased risk of death. Increased white blood cell count, decreased lymphocyte and platelet counts, were also associated with increased risk of death. Biomarkers of coagulation function, inflammation, liver and kidney function, cardiac and muscle injury were also elevated in nonsurvivors. CONCLUSIONS: Male, current smoking patients aged 60 years or over might face a greater risk of in-hospital death and the comorbidities such as diabetes, hypertension, CVD, respiratory disease, and CKD could also influence the prognosis of the COVID-19. Clinical feature such as dyspnea and fatigue could imply the exacerbation and even death. Our findings highlighted early markers of mortality which were beneficial to identify fatal COVID-19.
Authors: Anne E Watt; Norelle L Sherry; Patiyan Andersson; Courtney R Lane; Sandra Johnson; Mathilda Wilmot; Kristy Horan; Michelle Sait; Susan A Ballard; Christina Crachi; Dianne J Beck; Caroline Marshall; Marion A Kainer; Rhonda Stuart; Christian McGrath; Jason C Kwong; Pauline Bass; Peter G Kelley; Amy Crowe; Stephen Guy; Nenad Macesic; Karen Smith; Deborah A Williamson; Torsten Seemann; Benjamin P Howden Journal: Lancet Reg Health West Pac Date: 2022-06-03
Authors: Gianluca Ciuffreda; Sara Cabanillas-Barea; Andoni Carrasco-Uribarren; María Isabel Albarova-Corral; María Irache Argüello-Espinosa; Yolanda Marcén-Román Journal: Int J Environ Res Public Health Date: 2021-11-12 Impact factor: 3.390
Authors: Rebecca Grainger; Alfred H J Kim; Richard Conway; Jinoos Yazdany; Philip C Robinson Journal: Nat Rev Rheumatol Date: 2022-02-25 Impact factor: 32.286